Table of Contents
From the Editor
- COX-2 inhibitors: Balancing the hope, the hype, and the concern
When all is said and done, the choice rests with the individual prescribing physician.
Medical Grand Rounds
- Management of primary headache: Serendipity and science
A capsule summary of the current management of migraine, chronic tension headache, and cluster headache.
- Chronic myelogenous leukemia: The news you have and haven’t heard
One major advance in treating CML was widely publicized. Another, although equally important, was not.
Review
- Recognizing and treating diabetic autonomic neuropathy
Strict glycemic control can slow the onset of diabetic autonomic neuropathy and sometimes reverse it. Other treatments address specific symptoms.
- Role of alendronate and risedronate in preventing and treating osteoporosis
A review of the efficacy and use of the two oral bisphosphonates approved for preventing and treating osteoporosis.
The Clinical Picture
1-Minute Consult
How often are atrial septal defects associated with thromboembolism? When should they be looked for?In the absence of other causative conditions, an atrial septal defect may be presumed to be the underlying cause of a stroke, especially in younger patients.
Editorial
- Cox - 2 Inhibitors and Cardiovascular Risk
Even if we do not know with certainty whether COX-2 inhibitors increase the risk of cardiovascular events, we need to incorporate this concern into our practice.
Point and Counterpoint
- Cox - 2 Inhibitors and Cardiovascular Risk
Unless a clear cause-and-effect relationship can be proved between COX-2 inhibitors and cardiovascular events, we should go on using these drugs.
- Cox - 2 Inhibitors and Cardiovascular Risk
Our study had limitations, but we believe our hypothesis is plausible, our methods were valid, and our conclusions are sound.
